Evidence map›Paper›PMID 27043680›Full record

ArticleMedicine2016

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.

Nada El Ghorayeb, Geneviève Rondeau, Mathieu Latour, Christian Cohade, Harold Olney, André Lacroix, Paul Perrotte, Alexis Sabourin, Tania L Mazzuco, Isabelle Bourdeau

Erratum issuedOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2020
    Review
  6. Observational
  7. Article
  8. The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018
    Article
  9. Adrenocortical carcinoma characterized by gynecomastia: A case report.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2018
    Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Nada El GhorayebFrom the Division of Endocrinology (NEG, GR, AL, IB), Department of Medicine; Department of Pathology (ML); Division of Nuclear Medicine (CC), Department of Radiology; Division of Oncology (HO), Department of Medicine; Division of Urology (PP), Department of Surgery; Division of Endocrinology (AS), Department of Medecine, Hôpital Honoré Mercier, Saint-Hyacinthe, Québec, Canada; and Division of Endocrinology (TLM), Medical Clinical Department, Health Sciences Centre, Universidade Estadual de Londrina (UEL), Paraná, Brazil.
Geneviève Rondeau
Mathieu Latour
Christian Cohade
Harold Olney
André Lacroix
Paul Perrotte
Alexis Sabourin
Tania L Mazzuco
Isabelle Bourdeau
Universidade Estadual de Londrina · BR

Funding

Canadian Institutes of Health Research 201209NMD
6 · The paper itself

Abstract

Mitotane has been used for more than 5 decades as therapy for adrenocortical carcinoma (ACC). However its mechanism of action and the extent of tumor response remain incompletely understood. To date no cases of rapid and complete remission of metastatic ACC with mitotane monotherapy has been reported. A 52-year-old French Canadian man presented with metastatic disease 2 years following a right adrenalectomy for stage III nonsecreting ACC. He was started on mitotane which was well tolerated despite rapid escalation of the dose. The patient course was exceptional as he responded to mitotane monotherapy after only few months of treatment. Initiation of chemotherapy was not needed and he remained disease-free with good quality of life on low maintenance dose of mitotane during the following 10 years. A germline heterozygous TP53 exon 4 polymorphism c.215C>G (p. Pro72Arg) was found. Immunohistochemical stainings for IGF-2 and cytoplasmic β-catenin were positive. Advanced ACC is an aggressive disease with poor prognosis and the current therapeutic options remain limited. These findings suggest that mitotane is a good option for the treatment of metastatic ACC and might result in rapid complete remission in selected patients.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAntineoplastic Agents, Hormonalbeta CateninCanadaGenes, p53HumansInsulin-Like Growth Factor IIMaleMiddle AgedMitotaneNeoplasm MetastasisPolymorphism, Single NucleotideQuality of LifeRemission InductionAntineoplastic Agents, Hormonalbeta CateninIGF2 protein, humanInsulin-Like Growth Factor IIMitotane

Identifiers

PMID27043680
PMCPMC4998541
OpenAlexW2411589889

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.